NCT05150054View on ClinicalTrials.gov

MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

July 18, 2023

Study Completion Date

July 30, 2023

Conditions
Coronary Microvascular DysfunctionIschemic Non-Obstructive Coronary Artery Disease
Interventions
DEVICE

CardioFlux

Not an intervention

Trial Locations (4)

44195

Cleveland Clinic, Cleveland

45040

Genetesis Facility, Mason

45219

The Christ Hospital, Cincinnati

48236

Ascension St. John, Detroit

Sponsors

Lead Sponsor

Genetesis Inc.
All Listed Sponsors
lead

Genetesis Inc.

INDUSTRY

NCT05150054 - MCG as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction | Biotech Hunter | Biotech Hunter